医院药品风险管理情况分析及防范措施

目的 分析医院药品的风险管理情况.方法 对北京世纪坛医院2010年1月至2012年12月药品采购、入库验收、药品调剂、药品保管及使用过程药品质量问题进行统计分析.结果 2010年1月至2012年12月入库验收存在问题47种[2010年12种,检验报告0种（0.0％）、药品外观6种（50.0％）、标签1种（8.3％）、5种（41.7％）;2011年21种,检验报告2种（9.5％）、药品外观4种（19.0％）、标签2种（9.5％）、发票信息9种（61.7％）;2012年14种,检验报告1种（7.1％）、药品外观7种（50.0％）、标签0种（0.0％）、发票信息6种（42.9％）],调剂和临床使用中药剂出现问题49种（2010年15种、201 1年12种、2012年22种）,召回药品11种（2010年3种、2011年4种、2011年4种）.结论 医院存在不同程度的药品管理风险,需要加强防范措施.     

1HNMR- PR研究4种基源种川贝母的整体差异性

目的 比较川贝母4种基源种的种内、种间化学成分的整体差异性.方法 采用1 HNMR采集川贝母样品的信息,采用模式识别分析法中的聚类分析、主成分分析法分析信息.结果 4种川贝母基源种间的相似度较高,但种内、种间样品存在细微差异.同一基源种川贝母样品间的主要差异体现在成分的含量上,而不同基源种样品间则存在成分含最和成分类别...     

养生格言

健康十个一 一个宽阔的胸怀,一种规律的生活,一种合理的饮食习惯,一种适合自己的锻炼方法,一种活泼热情开朗合群的性格,一种能调节心身的业余爱好,一种不向任何压力低头的意志,一种对待疾病的正确态度,一种对年龄的忘却,一个永远微笑的面孔。     

呼吸系统药物用药分析

目的 评估我院呼吸系统药物应用情况.方法 调查统计本院2008 ～ 2010年的呼吸系统药物使用品种、购药金额,分析临床使用情况.结果 2008年呼吸系统药物28种,药品销售金额108.99万元,占全院药品总销售金额(13 235.50万元)的0.82％.2009年呼吸系统药物27种,药品销售金额170.86万元,占全院药品总销售金额(19 345.80万元)的0.88％.2010年呼吸系统药物38种,药品销售金额190.39万元,占全院药品总销售金额(17 380.25万元)的1.10％.2008年呼吸系统药物28种,其中镇咳类药物2种、祛痰类药物4种、平喘类药物16种、中药制剂6种.2009年呼吸系统药物27种,其中镇咳类药物1种、祛痰类药物5种、平喘类药物13种、中药制剂8种.2010年呼吸系统药物38种,其中镇咳类药物1种、祛痰类药物7种、平喘类药物19种、中药制剂11种.结论 我院呼吸系统用药金额增长,结构稳定.     

日本正仓院唐代药物基原研究

日本正仓院《种种药账》中记载60种药物,帐内未记载药物尚有20余种.为了解药物品种沿革,对药帐内外各药情况进行总结.帐内药物:16种品种未改变,沿用至今；5种名称改变,药物仍在使用；6种与今天基原不同；1种今用其替代品；13种尚待进一步考证；19种药物帐内有记载,实物不存.帐外药物:8种沿用至今,且基原相同；2种与今不同；其他有待进一步考证.     

国际临床药学期刊简介

据2009 ISI SCIE源刊信息,SCIE已收录世界药学期刊216种,其中属于临床药学的期刊(在英文刊名中带CLINICAL词的期刊)为23种,分布于8个国家:美国11种,英国4种,德国和新西兰各2种,澳大利亚、丹麦、西班牙和意大利各1种.     

中国药典2020年版(一部)收载毒性中药及其注意事项统计分析

摘要：本文对中国药典2020年版一部收载的616种中药中的毒性中药品种及其性能特点进行统计分析。结果表明,中国药典2020年版共收录毒性中药83种,其中含大毒有10种、有毒42种、小毒31种;毒性中药中属温、热性的药物有46种,寒凉性的药物26种,属平性的药物4种;具辛、苦味共计有71种;归肝经29种、肺经28种。进一步对用药注意及禁忌进行分析,以期全面认识与深刻理解毒性中药,掌握其性能、用法用量、注意事项等,预防药品的不良反应,杜绝药物的滥用。     

护理标识在病区细化管理中的应用和体会

细化管理是一种先进的管理文化和管理方式.细化是一种意识、一种观念、一种认真的态度、一种精益求精的文化."细"可以解释为更加具体、缜密、更好、更优、精益求精.     

襄阳地区药用动植物资源分布调查

目的:调查襄阳地区药用动植物资源分布状况,包括重点品种、一般品种及栽培品种的具体情况。方法:采用查阅文献、走访和实地考察等方法,明确襄阳市药用动植物资源的分布状况。结果:普查结果表明襄阳地区分布常用药用动植物达918种,其中,菌类植物5科9属12种;地衣植物1科1属2种;苔藓植物3种4属7种;蕨类植物19科26属38种;裸子植物8科15属18种;被子植物138科514属765种;动物类51科64属77种。本地栽培的主要药材52种,新发现中药36种。结论:建议当地政府积极引导农民在环境适宜区开展人工栽培,合理开发利用本地区中药资源。     

当心保健品里的药性

根据国家药监局的有关规定,保健食品大致分为两种,一种为营养素补充剂,其保健功能是补充一种或多种人体所必需的营养素;另一种     

Modulatory effect of isoprinosine on lymphocyte proliferative response under immunodepressive conditions

In the present work the effect of Isoprinosine on the mitogenic responses of T and B lymphocytes has been studied. We have found that Isoprinosine can enhance in vitro the response to Concanavalin A. This enhancement was more apparent in cell cultures showing an initially low blastogenic response. In low responses artificially induced by treatments in vivo with cyclophosphamide, our results indicate that Isoprinosine, administered in vivo, does not enhance the response to Con A of treated mice. However, addition of Isoprinosine (75 micrograms/ml) to cultures of spleen cells from mice previously treated with cyclophosphamide enhanced the suppressed response up to normal levels. Neither in vivo nor in vitro Isoprinosine treatments increased the response of lymphocytes to lipopolysaccharide, but usually inhibited the blastogenesis of B cells.     

Enhancement and restoration of contact sensitivity reactions by isoprinosine

Isoprinosine (50 mg/kg i.p.) increased the ear swelling reaction in mice sensitized with trinitro-chlorobenzene (picryl chloride) and challenged with the same agent. Enhancements were observed when the drug was administered either simultaneously to the sensitization or to the challenge with picryl chloride. Similar results were obtained when lymphoid cells from sensitized animals were transferred i.v. to normal animals which were then challenged with picryl chloride. Using the same cell transfer system, we found that treatment of cell donors with Isoprinosine (50 mg/kg/day, i.p.) counteracts the inhibition induced by cyclophosphamide. Isoprinosine (50 mg/kg/day, i.p.) inhibited also the generation of antigen-specific suppressor cells induced by picryl-sulfonic acid as shown by transfer to normal recipients of suppressor cells together with lymphoid cells from sensitized animals. These results indicate that Isoprinosine enhances normal contact sensitivity reactions and can counteract, under certain circumstances, antigen-specific as well as nonspecific immunosuppression.     

Isoprinosine as an immunopotentiator.

Isoprinosine is a compound developed for antiviral use. The effects of isoprinosine on mouse responses to sheep red blood cells were studied over a wide range of doses, from 0.5 microgram/kg to 5 g/kg, i.p. administered at the time of i.v. immunization or as pretreatment for 7 days before antigenic stimulus. Low doses, 50 microgram/kg to 50 mg/kg, significantly increased the numbers of IgM- or IgG-spleen antibody-forming cells. Large doses, such as the LD50 (5 g/kg) or pretreatments where unable to impair mouse immune responsiveness. Isoprinosine (< 500 mg/kg/day) orally administered at time of or one day after immunization stimulated immune responses. In vitro addition of isoprinosine to spleen lymphocytes augmented PHA- or Con A-induced proliferation over a concentration range from 10 to 150 microgram/ml, whereas isoprinosine had no effect in the absence of mitogens. These data, and the lack of immunodepressing effect, suggest that there is a need for further evaluation of isoprinosine as an immunopotentiator.     

Differentiation and regulation of lymphocyte populations: evidence for immunopotentiator-induced T cell recruitment.

Isoprinosine, the p-acetaminobenzoic acid salt of inosine dimethylaminoisopropanol (1:3 molar ratio) and sodium diethyldithiocarbamate are two immumopotentiators which share an ability to induce in vivo acquisition of a specific T-cell marker by undifferentiated precursor lymphoid cells of healthy nu/nu mice, without affecting the B-cell lineage. Serum from treated nu/nu mice tested in dual assays, contains a selective inducer of prothymocytes.     

Inosiplex: metabolism and excretion of the dimethylaminoisopropanol and p-acetamidobenzoic acid components in rhesus monkeys

The principal excretion products derived from radiolabeled N,N-dimethylaminoisopropanol (Dip) and p-acetamidobenzoic acid (PAcBA) components of inosiplex (Isoprinosine) were identified and quantified in urine following single iv and oral administration of the drug in rhesus monkeys. The major metabolite derived from [3H] PAcBA was identified as PAcBA-O-acylglucuronide by 1) positive naphthorescorcinol reaction for glucuronic acid and 2) hydrolysis of the metabolite to PAcBA and glucuronic acid, using either dilute base (but not acid) or beta-glucuronidase. This metabolite accounted for 50% of the administered dose in orally dosed animals and 31% in iv dosed animals. A minor metabolite, which constituted approximately 5% of the excreted 3H from either iv or orally dosed animals, was identified as the hippuric acid conjugate of PAcBA by co-chromatography with a commercial standard. A single metabolite derived from [14C]Dip was identified as Dip-N-oxide by co-chromatography with synthetic material in several chromatographic systems; this metabolite accounted for 17 to 18% of the administered 14C in either the iv or orally dosed animals.     

The effect of isoprinosine on the PHA response of monocyte-depleted and undepleted peripheral blood mononuclear cells

Isoprinosine has been reported to stimulate immunological responses involving different cell types. This study attempted to identify which cell type responds to isoprinosine in the blast transformation assay using the mitogen phytohemagglutinin (PHA). Human peripheral blood mononuclear cells, and the same cell population depleted of monocytes, were used to determine whether the absence of monocytes alters the response to isoprinosine. To determine whether there is a critical period of time during the assay when isoprinosine has its effect, the cells were selectively preexposed to drug and/or mitogen for a limited period of time, then cultured. Depletion of monocytes in itself augmented the response to mitogen, but the response could still be potentiated by isoprinosine, indicating that the drug's effect was on cells other than monocytes. Preexposure to isoprinosine and/or PHA, followed by culture with PHA with or without isoprinosine, showed that PHA initiates transformation within the first 3 hours and that initiation, a monocyte function, is not sensitive to isoprinosine. Both approaches suggest that isoprinosine does not affect monocytes and that it probably acts on T cells to produce its stimulatory effect in this in vitro assay.     

Microencapsulation of isoprinosine with ethylcellulose

Isoprinosine, an antiviral agent with a bitter taste, has been clinically used up to a maximum of 4 g daily in 4–8 doses. In this investigation, isoprinosine was microencapsulated with ethylcellulose 22 cps, 50 cps and 100 cps by means of polymer deposition from cyclohexane through temperature change. Complete removal of cyclohexane from the microcapsules was necessary, since ethylcellulose-coated microcapsules obtained from cyclohexane medium were heavily solvated with cyclohexane and formed lumps even after drying. The displacement of cyclohexane byn-hexane during isolation of microcapsules (Method III) or the freezing of the final-washed microcapsules before drying (Method II) provided the dried products which were more discrete microcapsules than those which were simply dried in the air overnight (Method I). Method III was especially the most effective procedure in preparing finer and more discrete microcapsules. The drug-release from microcapsules was influenced by the ratio of core to wall, the viscosity grade of ethylcellulose and the overall microcapsule size. The release rate was adequately fitted to both the first-order and the diffusion-controlled processes. It is therefore possible to design the release-controlled microcapsules with ethylcellulose of different viscosity along with various core to wall ratio.     

PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS

1. The development of the prejunctional receptor hypothesis . M.W. McCulloch, M.J. Rand and D. F. Story 2. Adrenoceptor- and cholinoceptor-mediated modulation of transmitter release at the somatic neuromuscular junction . C. Raper 3. Conditions of operation of positive and negative feedback regulation of transmitter noradrenaline release . D.F. Story and I.C. Medgett 4. Failure of a receptor blockade–a pre- and post-synaptic phenomenon . G.D.S. Hirst and T.O. Neild 5. Are radioligand assays useful for identification and characterization of prejunctional receptors? R.J. Summers and B. Jarrott 6. Prejunctional modulation of postganglionic cholinergic nerves . F. Mitchelson 7. Opiate receptor modulation of transmitter release . J.E. Olley* and A.L.A. Boura 8. Prejunctional receptors of human vascular sympathetic nerves . R.F. W. Moulds 9. Clinical implications of autonomic prejunctional receptors . J. Shaw 10. Correlations between the antihypertensive and haemodynamic effects of oxprenolol . R. Zacest, M.A. Robinson and L.L. Wilson 11. Comparison of long acting and short acting diuretics in mild essential hypertension . L.M.H. Wing, M.J. West, J.R. Graham and J.P. Chalmers 12. Effects on heart rate and blood pressure during graded exercise of beta adrenoceptor blocking drugs with and without intrinsic sympathomimetic activity (ISA) or ‘cardio-selectivity’ . G. Jennings, A. Bobik, P. Ashley, R. Newman, S. Ellet and P. Korner 13. Study of the effects of acute dosing with ac-methyl dopa on reflex autonomic tachycardia . A.J. McLean, G. Jennings and P.I. Korner 14. A study of in vitro vasoactivity of C.S.I, and the clinical state of patients who have had a subarachnoid haemorrhage . R.F.W. Moulds, C. Mylonas, R. Medcalfand D. Brownbill 15. Retrospective survey of digoxin usage . C. Corallo and K. Raymond 16. Dihydroergotamine kinetics in patients with orthostatic hypotension . A. Bobik, H. Skews, G. Jennings, M. Esler and P.I. Korner 17. Effect of probenecid on clofibrate disposition in man . J.R. Veenendaal. P.M. Brook and P.J. Meffin 18. Pharmacokinetics in human malnutrition . N. Buchanan 19. Impairment of an hepatic protective mechanism in man by food ingestion . A.J. McLean, C. Isbister, A. Bobik and F.J. Dudley 20. Carbamazepine monotherapy in epileptic patients . G.W. Mihaly and F.J.E. Vajda 21. Simultaneous determination of aspirin, salicyclic acid, salicyluric acid and gentisic acid in plasma by HPLC . R.H. Rumble and M.S. Roberts 22. Association between angiotensin conversion and prostacyclin release in isolated mesenteric vasculature of rats . G.J. Dusting and E.M. Mullins 23. Prostacyclin inhibits contractions of the rat isolated descending colon in response to field stimulation . I.R.N. Relf and A.L.A. Boura 24. Bradykinin induced spasm of the human umbilical vein is mediated via activation of phospholipase-A and potentiated by cooling . A.L.A. Boura, A.S.C. Sandford, R.J. McRae and W.A.W. Walters 25. L-Tryptophan-induced depression of α-adrenoceptor mediated vascular responses in the rat . P.L. Nolan and J.W. Caygill 26. Evidence against a physiological role of presynaptic alpha adrenoceptors in heart . J.A. Angus and P.I. Korner 27. The effect of DOCA hypertension on responses of the rat tail artery to potassium chloride and electrical stimulation . M.G. Venning and I.S. de la Lande 28. A possible histaminergic component of the clonidine withdrawal syndrome in the rat . S.J. Lewis, M.R. Fennessy and D.A. Taylor 29. Clonidine withdrawal syndrome and endogenous biogenic amines . D.A. Taylor, S.J. Lewis and M.R. Fennessy 30. The effects of sub-acute L-DOPA treatment of mice on L-DOPA-induced hyperactivity . O. Jenkins, R. Bailey, E. Crisp and D.M. Jackson 31. Chronic L-DOPA pretreatment of mice: production of dopamine receptor supersensitivity? R. Bailey, E. Crisp, D.M. Jackson and O. Jenkins 32. Accumulation of α-methylated phenolamines in rat brain after chronic administration of a-methyltyrosine . P.H. Duffield, D.F.H. Dougan, D.N. Wade and A.M. Duffield 33. Effect of unilateral lesions on octopamine and tyramine concentrations in rat striatum . D.F.H. Dougan, P.H. Duffield, D.N. Wade, A.M. Duffield and G. Paxinos 34. Effect of surgical denervation on α₁ and α₂-adrenoceptors in rat cerebral cortex . M.J. Morris, J.L. Elghozi, J.P. Dausse and P. Meyer 35. Localization of |³H|clonidine binding sites in membranes prepared from guinea pig renal cortex . G. McPherson and R.J. Summers 36. Characterization of (³H)cIonidine binding sites in membranes prepared from guinea pig spleen . R.J. Summers and G. McPherson 37. Alpha-adrenergic receptors modulate agonist affinity for beta-receptors in rat kidney membranes . E.A. Woodcock and C.A. Olsson 38. Pentobarbitone enhancement of GABA binding . M. Willow and G.A.R. Johnston 39. Stress induced changes in Leucine-enkephalin binding and plasma corticosterone in mice . M.J. Christie, P. Trisdikoon, J. Eross and G.B. Chesher 40. Duration of the analgesic effects of some opiate-like peptides following intracerebroven-tricular (i.c.v.) administration in the rat . M.J. Quinn and M.R. Fennessy 41. Relationship between δ⁹-tetrahydrocannabinol (δ⁹-THC) withdrawal behaviour and brain regional levels of histamine (HA) in the rat . A.J.M. Verberne, D.A. Taylor, S.J. Lewis and M.R. Fennessy 42. Long-term effects of a single dose of haloperidol or thioridazine on schedule induced drinking . G. Singer 44. Effect of o-methylflavinantine on contractions of the guinea-pig longitudinal muscle induced by co-axial electrical stimulation . R. Ansa-Asamoah and G.A. Starmer 45. Do endogenous purine nucleosides modulate the release of acetylcholine at the mammalian neuromuscular junction ? I. Spence 46. Effect of adrenaline on transmitter noradrenaline release . H. Majewski, M.W. McCulIoch, M.J. Rand and D.F. Story 47. Effects of tetrodotoxin on release of noradrenaline by nicotine in rabbit atria . C. Sarantos-Laska, M.W. McCulloch, D.F. Story and M.J. Rand 48. The effect of ventilatory gas composition on arachidonic acid metabolism in isolated perfused guinea-pig lungs . V. Iwanov, J. Staszewska-Barczak and G.J. Dusting 49. An isolated perfused adrenal preparation for studying adrenal catecholamine secretion . A.R. Collett and D.F. Story 50. Inhibition of nerve-mediated contractions in isolated guinea-pig ileum by 1-methyliso-guanosine, a novel purine from a sponge . D. Jamieson and P. Davis 53. β-Adrenoceptors and catecholamine-induced responses of human and porcine peripheral lung strip : Effects of uptake inhibitors. R.G. Goldie and G.M. Ellis 54. Uptake and release of N-methyl-D-aspartate by rat brain slices . J.H. Skerritt and G.A.R. Johnston 62. Receptor binding assay for detection of endogenous opioids . P.M. Lewis and J.E. Olley 63. Prospective drug utilization study of antibiotics based on blood level assays . A. Saunders and K. Raymond 57. The pharmacokinetics of chlorbutol . C. Tung, G.G. Graham, D.N. Wade and K.M. Williams 58. Effect of desmethylimipramine on the anorectic activity and tissue distribution of chlorphentermine in rats . R.F. Minchin, K.F. Ilett and B.W. Madsen 59. Effects of a new monoamine oxidase-A selective inhibitor (MD780515) on amine metabolism in the small intestine . K.F. Ilett, C.F. George and D.S. Davies 60. Hepatic elimination of sodium valproate (SV). F.J.E. Vajda, A.W. Marshall, G.W. Mihaly, R.A. Smallwood, J. Baldas and J. Phillips 61. A sensitive method for measurement of catecholamines and their metabolites in extracts of small brain areas . P.R. Rowe, R.J. Summers and P.M. Beart 62. Receptor binding assay for detection of endogenous opioids . P.M. Lewis and J.E. Olley 63. Prospective drug utilization study of antibiotics based on blood level assays . A. Saunders and K. Raymond 64. Gastric absorption of valproate in rats . N.D. Yeomans, F.J.E. Vajda and J. Baldas 65. Elimination kinetics of labetalol in severe renal failure . D.G. Ferry, A.J. Wood and R.R. Bailey 66. High pressure liquid chromatographic analysis of ranitidine. G.W. Mihaly, O.H. Drummer, A.W. Marshall, W.J. Louis and R.A. Smallwood 67. Model independent pharmacokinetics of slow intravenous infusions. K. Raymond and D.J. Morgan 68. Fate of oral hydrallazine in slow and fast acetylators. I. Cozamanis, P.A. Reece and R. Zacest 69. Pharmacokinetics of perhexiline maleate in patients with angina pectoris. J.D. Horowitz, P.M. Morris, A.J. Goble and W.J. Louis 70. The pharmacokinetics of midazolam in man. M.T. Smith, M.J. Eadie, T. O'Rourke-Brophy and T.C. Smith 71. The perinatal disposition of thiopentone. L. Wolf, D.J. Morgan, G.L. Blackman and J.D. Paull 72. Minor metabolites of 5-fluorocytosine in man. K.M. Williams, A.M. Duffield, R.K. Christopher and P.J. Finlayson 73. Steady-state bioavailability of a slow release theophylline formulation in children with acute asthma. D.J. Birkett, K. Coulthard, J.O. Miners, J.J. Grygiel, N. Grgurinovich and D. Lines 74. Protein binding of non-steroidal anti-inflammatory drugs in rheumatoid arthritis. S. Wanwimolruk, D.J. Birkett and P. Brooks 75. The measurement of mouth-caecal transit time using salicylazosulphapyridine. E.J. Begg, M. Kennedy, P.M. Chinwah and D.N. Wade 76. Mechanisms of acute hypertension and bradycardia following intracisternal 6-hydroxy-dopamine in conscious rabbits. G.A. Head and P.I. Koraer 77. Effects of dopamine on renal function and kallifrein excretion in the isolated perfused rat kidney. B.P. McGrath, P.G. Matthews, L. Leversha, P. Jablonski and B. Howden 78. A comparison of the effects of Endrallazine and Hydralazine on isolated human arteries and veins. S. Lipe, R. Medcalf, V. Iwanov and R.F.W. Moulds 79. Studies on amphetamine-induced circling in rats with substantia nigra lesions. J.S. McKenzie, S. Hannigan and A. Churchyard 80. Further studies on the peripheral antinociceptive action of morphine. G.A. Bentley, S.H. Newton and Jennifer Starr 81. Chronic haloperidol treatment of rats and a-adrenergic receptor sensitivity. A. Per ring-ton, R. Einstein and D.M. Jackson 82. Anticonvulsant activity of propranolol. Jenny Papanicolaou, F.J.E. Vajda and W.L Louis 83. Glycine and dopamine in the ventral tegmental area of the rat. A.L. Gundlach, D. McDonald and P.M. Beart 84. Effects of beta-adrenoceptor antagonists on the haemoglobin-oxygen (Hb-O) dissociation curve in vitro and in vitro. P.W. Trembath, E.A. Taylor, M. Roberts, and J. Amess 85. Clonidine analogues and hypothermia in mice. P.L. McLennar 86. Myolytic effects of Australian snake venoms in monkeys (Macaca fascicularis). S.K. Sutherland and D.G. Campbell 87. Prevention of sulphur-induced bronchoconstriction by disodium cromoglycate (DSCG) and Ketotifen. Diana M. Temple     

Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists

12th Annual Meeting, 4-6 December 1978, Monash University, Clayton, Victoria 1. A dopamine activated inhibitory feedback loop during prolonged sympathetic nerve stimulation. H. Majewski, M. J. Rand and D. F. Story 2. The actions of noradrenaline at pre-junctional adrenoceptors in the rat vas deferens in the presence of neuronal uptake inhibitors . Susan E. Wanning, Jocelyn N. Pennefather and Gwynneth M. Handberg 3. Preliminary studies on transmitter release from isolated human digital arteries . R. E. Rittinghausen and R. F. W. Moulds 4. Effects of adrenaline and adrenergic nerve stimulation on airway smooth muscle in guinea-pigs and rabbits . J. M Doidge and D. G. Satchell 5. Does sympathetic nerve stimulation alter the response of muscle blood vessels to adrenaline in the dog? T. M. Christof and W. E. Glover 6. Investigation of possible heterogeneity of human vascular a-adrenoceptors M. J. Stevens and R. F. W. Moulds 7. Uptake and metabolism of noradrenaline in the brain of the possum (Trichosurus vulpecula). J. Minson and I. S. de la Lande 8. Selective inhibition of muscarinic receptors. C. K. Li and F. Mitchehon 9. Preliminary studies using R0363, a β₁-adrenoceptor selective agonist. G. A. Mcrherson, C. Raper and D. Iakovidis 10. Examination of propranolol analogues for β₂-selectivity using guinea-pig isolated trachea and atria. Stella R. O'Donnell, Karin Walduck and Janet C. Wanstall 11. Fluorescence histochemical study of effects of catechoI-O-methyl transferase inhibitors on extraneuronal accumulation of isoprenaline in guinea-pig trachealis smooth muscle. Lesley J. Bryan and Stella R. O'Donnell 12. A histochemical study on isoprenaline accumulation demonstrates differences between guinea-pig atria and trachea. Elizabeth N. Anning and Stella R. O'Donnell 13. The antiarrhythmic actions of Kö1875, a quaternary derivative of the β-receptor antagonist bunitrolol. G. S. Keh, C. Raper and E. J. Mylecharane 14. The effects of changes in thyroid state upon atrial α- and β-adrenoceptors, adenylate cyclase activity and catecholamine levels in the rat. E. J. N. Ishac, Jocelyn N. Pennefather and Gwynneth M. Handberg 15. Metabolism of intraluminal and extraluminal noradrenaline in the rabbit ear artery. I. S. de la Lande, R. G. Morris, R. Irvine 16. A pharmacological comparison of isolated human cerebral and digital arteries. G. A. Rose, P. J. Worland and R. F. W. Moulds 17. Comparative pharmacokinetics of quine and quinidine. G. Graham, P. Carroll, T. M. Haavisto, A. Lau and C. Liddle 18. A pharmacokinetic approach to pain control: I. Multiple intramuscular injections. K. L. Austin, J. V. Stapleton. L. E. Mather 19. A pharmacokinetic approach to pain control: II. Continuous intravenous infusions. L. E. Mather, K. L. Austin and J. V. Stapleton 20. Comparison of oral and intravenous high dose methotrexate therapy in outpatients. J. Marty, J. Shaw and J. Sullivan 21. Influence of infusion time on simulated plasma concentrations of trimethoprim and sulphamethoxazole. D. J. Morgan and K. Raymond 22. Bioavailability of two formulations of carbimazole. G. M. Shenfield, K. F. Ilett and R. Tjokrosetio 23. The effect of food on phenytoin absorption. M. Kennedy and D. N. Wade 24. Surface deposition of griseofulvin on carriers: bioavailability studies. R. S. Wagner, B. G. Charles and J. L. Lach 25. Availability of nitroglycerine from plastic infusion sets. G. W. Boyd, M. S. Roberts, A. J. Galbraith and P. A. Cossum 26. Plasma levels of mexiletine in patients treated for acute and chronic ventricular tachyarrhythmias. J. D. Horowitz, S. N. Anavekar, P. Morris, A. J. Goble, A. E. Doyle and W. J. Louis 27. Absorption and excretion of rapid and slow release oxprenolol formulations and their effects on heart rate and blood pressure at rest and during exericse. A. Bobik, G. L. Jennings, P. I. Komer, P. Ashley and G. Jackman 28. Dose-dependent pharmacokinetics of prednisolone in man. A. R. Tanner, F. Bochner, J. A. Caffin, J. W. Halliday and L. W. Powell 29. The effects of sex steroid hormone pretreatment on the hepatic microsomal detoxifying system in female mice. M. Willow, R. Malor and L. B. Cobbin 30. Effects of allopurinol and sulphaphenazole on the plasma clearance and metabolism of theophylline (1,3-dimethylxanthine) in man. J. J. Grygiel, L. M. H. Wing and D. J. Birkett 31. The effect of hepatic cirrhosis on the pharmacokinetics of chlormethiazole K. J. Breen, R. W. Bury, I. D. Mansell, M. L. Mashford and Marion Peters 32. Metabolism of salicylate during chronic aspirin therapy. R. H. Rumble, M. S. Roberts and P. M. Brooks 33. Metabolism of phenacetin and N-hydroxyphenacetin in isolated rat hepatocytes. S. McLean 34. Kinetics of methanol in sheep breathing vapour from a petrol-methanol mixture. E. G. McQueen and D. G. Ferry 35. Effect of sleep on Michaelis-Menten elimination of ethanol. L. Rossi and B. W. Madsen 36. The role of concentration-dependent plasma protein binding in disopyramide disposition . P. J. Meffin, E. W. Robert, R. A. Winkle, S. R. Harapat, F. A. Peters and D. C. Harrison 37. Pharmacokinetics of disopyramide after acute myocardial infarction. K. F. Ilett, B. W. Madsen and J. D. Woods 38. Pulmonary accumulation of imipramine: species and dose dependence. R. Drew, Z. H. Siddik, E. G. Mimnaugh and T. E. Gram 39. Plasma protein binding and salivary concentrations of theophylline. D. J. Birkett, J.F. Hagedorn, L.M.H. Wing and J. J. Grygiel 40. Pharmacokinetic studies of sodium valproate following acute and chronic administration in epileptic patients. G. W. Mihaly, J. Miles, W. J. Louis and F. J. E. Vajda 41. The pharmacokinetics of metoclopramide. L. M. Cotter, M. J. Eadie and J. H. Tyrer 42. Adrenal angiotensin receptor in experimental hypertensions and altered sodium status. P. G. Matthews, M-A. Devynck, M-G. Pernollet and P. Meyer 43. Venoconstrictor activity of some precursor fractions of stable plasma protein solution (SPPS). J. D. Horowitz and M. L. Mashford 44. Prostaglandin release from isolated tissues of the rat. Molly Thomas and A. L. A. Boura 45. Contraction of the human umbilical vein caused by decreased temperature is accompanied by release of prostaglandins and reduced after inhibition of prostaglandin synthesis. T. A. Sinnathuray, Lyndall Boyle, W. A. W. Walters and A. L. A. Boura 46. Effect of putative peptide neurotransmitters on cutaneous vascular permeability in the rat. Loris A. Chahl 49. Does histamine regulate sympathetic effects on arterial smooth muscle? A. Foldes 48. Sympathetic nerves, prostaglandins and renal blood flow regulation in conscious rabbits. L. J. Beilin, and J. Bhattacharya 49. Effect of 4-aminopyridine on isolated rabbit atria. W. E. Glover 50. Plasma renin rebound following salicylate therapy in man. P. M. Brooks, P. Cossum and G. W. Boyd 51. Medroxyprogesterone and autoimmune liver disease: effects on liver function and drug metabolism. E. A. Sotaniemi, T. Hynnynen, J. Ahlqvist, J. T. Ahokasf, U. Puoskari and I. Pelkonen 52. A phenacetin breath test of hepatic metabolising capacity. K. J. Breen, R. W. Bury, M. L. Mashford and Marion Peters 53. Gentamicin usage and incidence of gentamicin-resistant bacteria in Sydney Hospital: an event orientated drug usage study. P. F. Anderson, G. M. Eckert and D. M. Jackson 54. Indapamide in essential hypertension. S. N. Anavekar, A. Ludbrooke, W. J. Louis and A. E. Doyle 55. Psychological influences and drug treatment for essential hypertension. C. G. Barrow and R. Zacest 56. Indoramin and prazosin as adjuncts to beta-adrenoreceptor blockade in treatment of hypertension. G. S. Stokes, G. W. Frost, R. M. Graham and E. P. MacCarthy 57. Intravenous labetalol in accelerated hypertension. L. M. H. Wing, J. B. Mulligan, M. J. West, J. P. Chalmers, D. J. Pugsley and A. R. Clarkson 58. Clinical and pharmacological effects of atenolol (tenormin). B. McGrath, L. J. Beilin, T. Schofield and C. Benedict 59. Acute and chronic response to dihydroergotamine (DHE) in patients with orthostatic hypotension. G. L. Jennings, Romayne I. Holmes, M. Esler and P. I. Korner 60. Factors determining re-admission to a university teaching hospital. J. Shaw and J. D. Hobson 61. Initial experience of a pharmacokinetically based drug consultation service. G. Taylor, A. J. McLean, P. du Souich, D. Lalka, T. Ludden, C. Walton and J. L. McNay 62. Clonidine distribution in rat tissues after intravenous administration. E. L. Conway & B. Jarrott 63. Effects of clonidine analogues on gastric acid secretion in the anaesthetized rat. I. C. Medgett and M. W. McCulloch 64. Interaction of clonidine metabolites with an a-adreno receptor in rat brain membranes. B. Jarrott, W. J. Louis and R. J. Summers 65. Central and peripheral effects of α-adrenoreceptor agonist drugs on somato-sympathetic reflexes. R. M. Brazenor and G. A. Bentley 66. Effect of L-tryptophan pretreatment on the vascular response to noradrenaline in the rat. R. Mullaly and P. L. Nolan, (introduced by G. A. Bentley) 67. Inter-relationship between vasoconstriction and bradycardia caused by St 91. P.L. McLennan and G. A. Bentley 68. Inhibition of cardiac vagal efferent nerve activity by intravenous administration of angiotensin II. Erica K. Potter, Eugenie R. Lumbers and D. I. McCloskey 69. Hypotensive activity of an orally active converting enzyme inhibitor in spontaneously hypertensive rats. J. S. Hutchinson, F.A.O. Mendelsohn, A.E. Doyle and S. Duffy 70. Effects of cyclopenthiazide on blood pressure and plasma renin activity in hypertension. R. Zacest, L. L. Wilson, G. C. Scroop, J. R. Graham, C. D. H. Miller and M. O'Halloran 71. The cardiovascular and renal actions of SAR₁THR₈ angiotensin II in the conscious sheep. R. B. Cross, K. Wilson, M. C. Khosla and F. M. Bumpus 72. Cardiovascular and renal actions of MK-447. R. T. Mason and J. Staszewska-Barczak 73. Uptake of cardiac glycosides by hyperthyroid rat hearts. M. Veroni and G. M. Shenfield 74. Changes in albumen-binding capacity with polyarthritis. S. P. Davies 75. Determination of trimethoprim and sulphamethoxazole in human plasma by high pressure liquid chromatography. R. W. Bury and M. L. Mashford 76. A sensitive HPLC assay for 5-fluorouracil (5FU): a comparison with GLC. N. Christophidis, G. Mihaly, F. Vajda and W. Louis 77. Cortisol binding to human corticosteroid binding globulin. Utz W. Mueller and Julia M. Potter 78. Studies on the movement and effects of tiger snake (Notechis scutatus) venom in monkeys (M. fascicularis). S. K. Sutherland, A. R. Coulter and R. D. Harris 79. Halothane hepatotoxicity in an animal model with relevance to man. M. J. Cousins, J. H. Sharp, G. K. Gourlay, J. F. Adams, W. D. G. Haynes, and R. Whitehead 80. Relationship of structure to gastric ulcerogenic activity of salicylates and other antiinflammatory drugs. K. D. Rainsford 81. The effect of Δ9-tetrahydrocannabinol. (THC) on the kinetics of (Na+-K+)-ATPase of the synaptosomal plasma membrane from mouse cerebral cortex. R. Malor, D. M. Jackson, and G. B. Chesher 82. Δ9-tetrahydrocannabinol (THC): effect on phospholipid composition of certain mouse brain subcellular fractions. T. Hughes, R. Malor, D. M. Jackson and G. B. Chesher 83. Are drug-induced changes in platelet MAO activities relevant to psychiatry? K. G. Chamberlain and B. Davies 84. Effect of drugs on human blood platelet monoamine oxidase in vitro. P. A. Jacobs, B. M. Davies and T. R. Norman 85. Interaction of hydralazine with tension development and mechanisms of calcium accumulation in K⁺ stimulated rabbit aortic strips. A. J. McLean, P. du Souich, K. W. Barron and A. H. Briggs 86. The effect of dopamine and its agonists on phospholipid turnover in guinea-pig striatal synaptosomes. H. M. Allars, D. F. H. Dougan, K. F. O'Shea and D. N. Wade 87. Binding interaction of chlorphentermine and desmethylimipramine in rat lung subcellular fractions. R. F. Minchin, K. F. Ilett and B. W. Madsen 88. Effect of a convulsant barbiturate on the inhibitory action of GABA in the cat spinal cord. D. Lodge 89. Endogenous inhibitors of GABA binding to rat brain membranes. G. A. R. Johnston and S. M. E. Kennedy 90. Inhibition of GABA-transaminase by unsaturated GABA analogues. R. D. Allan, G. A. R. Johnston and B. Twitchin 91. The role of stress in increased naloxone potency induced by morphine pretreatment in mice. C. L. Wong and G. A. Bentley 92. Acute tolerance to ethanol. V. V. Schabinsky, G. A. Starmer, D. M. Jackson and R. Malor 93. Acute tolerance to the effects of ethanol induced by a high dose of ethanol. R. K. C. Teo and G. A. Starmer, T.A.R.U. 94. The effects of acute and chronic morphine administration on brain regional histamine levels in the rat. S. J. Lewis and M. R. Fennessy 95. Dopamine, the nucleus accumbens and active avoidance in rats: specificity of action. P. Braes and D. M. Jackson 96. Hyperkinesis in mice following withdrawal from chronic haloperidol. Robin Dunstan and D. M. Jackson 97. The effect of acute ethanol on body temperature and brain histamine levels in mice. Jenny Papanicolaou and M. R. Fennessy 98. Time-course of the effects of chronic A9-tetrahydrocannabinol in the rat. D. A. Taylor and M. R. Fennessy 99. Self-administration of nicotine by rats over a 28-day period. Lesley A. Smith and W. J. Lang 100. Amino acids act on developing chick brain to produce long-lasting changes in behaviour. L. J. Rogers, Howard, K. J. and Sdraulig. R. 101. Aspirin-caffeine interaction in the rat. Catherine Collins, R. Laird, G. A. Starmer and Solveig Weyrauch 102. Prejunctional a-receptor stimulant actions of clonidine-like drugs in the transmurally stimulated guinea-pig ileum. P. E. Kearney, E. Malta and C. Raper 103. Histamine H₂-receptor actions of clonidine-like drugs. J. S. B. Ong, P. E. Kearney, E. Malta, G. N. Vaughan and C. Raper 104. Components of the kinin system in plasma protein solution. P. B. Marley 105. Augmented naloxone potency following pretreatment with morphine plus muscarinic agonist drugs. G. A. Bentley and C. L. Wong 106. Cross-tolerance between ethanol and other anaesthetic agents. J. M. Wood and R. Laverty 107. Natural gastroprotectants against the ulcerogenic effects of aspirin and related drugs. K. D. Rainsford and M. W. Whitehouse 108. Computer based pharmacokinetic analysis. I. A pharmacokinetic package for the medical sciences (PPMS). K. L. Austin and L. E. Mather 109. Computer based pharmacokinetic analysis. II. Determination of pharmacokinetic constants after multiple infusions. L. E. Mather, R. L. Ringrose and K. L. Austin 110. HPLC determination of propranolol and metabolites in plasma and urine. M. Lo, P. A. Reece and S. Riegelman 111. Possible involvement of prostaglandins in the central and peripheral actions of morphine in the mouse. Mary Familari and A. L. A. Boura 112. Dopamine metabolism, as reflected by 3,4-dihydroxyphenylacetic acid (DOPAC) levels in the mesolimbic pathway of the rat. A. L. Gundlach and P. M. Beart 113. The influence of some neuroleptics on ³H-haloperidol binding to dopamine receptors. Fulton, A., Burrows, G.D., Scoggins, B.A. and Davies, B. 114. Regulation of prostacyclin (PGI2) formation in arterial endothelial cells. W. Hope, M. J. Doyle, C. Chesterman and T. J. Martin 115. Pharmacodynamics of β-adrenoceptor agonists at cardiac receptors. M. Sunbhanich and M. W. Nott 116. The antinociceptive effects of morphine and α-adrenoreceptor agonists. G. A. Bentley and J. Starr 117. Undergraduate practical pharmacology-drugs and the human cardiovascular system. Rosemarie Einstein, D. M. Jackson and E. J. Mylecharane 118. Evaluation of a test kit for tricyclic antidepressant determination. K. P. Maguire, G. D. Burrows, T. R. Norman and B. A. Scoggins 119. Radioimmunoassay of a new antidepressant–nomifensine. I. M. McIntyre, G. D. Burrows, T. R. Norman & B. A. Scoggins 120. Doxepin determination by gas liquid chromatography. J. M. E. Wurm, G. D. Burrows, T. R. Norman and K. P. Maguire 121. Determination of viloxazine by gas liquid chromatography. T. R. Norman, G. D. Burrows and J. M. E. Wurm 122. Drug usage data in planning the evaluation of therapy in a hospital. P. F. Anderson, G. M. Eckert and D. Jackson 123. Combined assay for antipyretic and anti-inflammatory activities. M. W. Whitehouse 124. The simultaneous analysis of theophylline, theobromine and caffeine in plasma by high performance liquid chromatography. J. O. Miners, D. J. Birkett and L. M. H. Wing 125. Nomifensine-a new antidepressant. P. Dumovic, G. D. Burrows, J. Vohra and I. M. Mclntyre 126. Relative potency of ipratropium bromide and fenoterol in asthma and chronic bronchitis. G. E. Marlin, D. E. Bush and N. Berend 127. Pharmacokinetics of a single 600 mg oral dose of doxycycline. G. E. Marlin, S. Cheng and W. Gunner 128. Effect of food on the bioavailability of erythromycin. J. Rutland, N. Berend and G. E. Marlin 129. Plasma levels of delta-1-tetrahydrocannabinol (THC) in humans after i.v., oral and smoke administration. S. Agurell, J. E. Lindgren, A. Ohlsson, L. Hollister, K. Gillespie and K. Knopes     

Response of rats to seizure stimulus modified by feeding

Wistar (W) and Sprague-Dawley (S.D.) rats responded differently to electroshock and metrazole test when fed with two diets (A and B). Latency periods of B for male (m) and female (f) were: W.m. greater than W.f. (P less than 0.001); W.m. greater than S.D.m. (P less than 0.05); S.D.f. greater than W.m. (P less than 0.001); S.D.m. B greater than S.D.m. A (P less than 0.001); W.m. B greater than W and S.D.m. A (P less than 0.001). Preconvulsive period for B were: W.f. and m. greater than S.D.f. and m. (P less than 0.001); W.m. greater than S.D.m. (P less than 0.001); W.m. greater than S.D.f. (P less than 0.001); S.D.m. greater than S.D.f. (P less than 0.001) and W.m. greater than W.f. (P less than 0.001). Effects of A were negligible. Phenytoin and phenobarbital protected against electroshock.